40 Securities Added to Nasdaq Biotechnology Index
Nasdaq recently announced the results of the annual re-ranking of the Nasdaq Biotechnology Index (NBI). The re-ranking was effective prior to market open on Monday, December 23, 2019. There are now 217 companies in the index, including 40 new additions. You can view the full list of securities here.
Since its inception, the NBI has shown impressive performance over the years. The market capitalization weighted index focuses specifically on the biopharmaceutical industry allowing Nasdaq-listed companies to gain exposure to passive investors.
Along with this performance was a substantial increase in assets under management (AUM) for IBB — the largest corresponding ETF that tracks the Nasdaq Biotechnology Index globally. In fact, the AUM as of December 31, 2019 was approximately $8B.
Nasdaq continues to be the leader in biotechnology listings, including initial public offerings in the biotechnology and pharmaceutical arena such as Genmab, Bridge Bio and Gossamer Bio, Inc. In 2019, Nasdaq had a 100% BioPharma IPO win rate as we welcomed 55 BioPharma IPOs raising approximately $5.6 billion in IPO proceeds.
If you have any questions, including how to leverage inclusion in the index, please do not hesitate to contact me at Jordan.Saxe@nasdaq.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Jordan Saxe
Nasdaq
Jordan B. Saxe is Senior Managing Director, Listing Services at Nasdaq. He is responsible for leading business development efforts in the healthcare sector, and brings over thirteen years of experience within the exchange field. He has advised over 200 IPOs and has worked closely with venture capital, private equity and investment firms to educate them on the liquidity options Nasdaq can provide. He holds a B.S. in Business Administration from the University of Vermont.
Read Jordan's Bio